These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16350873)

  • 1. Access to drugs for cancer: Does where you live matter?
    Menon D; Stafinski T; Stuart G
    Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?
    Gafni A; Birch S
    CMAJ; 2003 Apr; 168(7):849-51. PubMed ID: 12668543
    [No Abstract]   [Full Text] [Related]  

  • 6. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
    Shalansky SJ; Virk R; Ackman M; Jackevicius C; Kertland H; Tsuyuki R; Humphries K;
    Can J Cardiol; 2003 Feb; 19(2):173-9. PubMed ID: 12601443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
    Armstrong K; Mitton C; Carleton B; Shoveller J
    Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How expert opinion influences P&T decisions.
    Manag Care; 2010 May; 19(5):52. PubMed ID: 20524369
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees.
    Schiff GD; Tripathi JB; Galanter W; Paek JL; Pontikes P; Fanikos J; Matta L; Lambert BL
    Am J Health Syst Pharm; 2019 Apr; 76(8):537-542. PubMed ID: 30915453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breadth, Depth and Agreement among Provincial Formularies in Canada.
    Morgan S; Hanley G; Raymond C; Blais R
    Healthc Policy; 2009 May; 4(4):e162-84. PubMed ID: 20436800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities.
    Mittmann N; Knowles S
    Can J Clin Pharmacol; 2009; 16(1):e171-7. PubMed ID: 19242000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulators in access to anticancer drugs in Canada].
    Côté A; Keating B; Parent M; Simard G
    Sante Publique; 2015; 27(4):515-27. PubMed ID: 26751926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Public Health; 2002; 93(6):421-5. PubMed ID: 12448863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.